Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5073 - Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the CAPRI GOIM clinical trial


09 Sep 2017


Poster display session


Translational Research;  Colon and Rectal Cancer


Nicola Normanno


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


N. Normanno1, R. Esposito Abate1, M. Lambiase1, L. Forgione1, C. Cardone2, A. Iannaccone1, A. Sacco1, A.M. Rachiglio1, E. Martinelli3, D. Rizzi4, S. Pisconti5, G. Cartenì6, R. Bordonaro7, T. Troiani3, F. Giuliani8, S. Leo9, S. Romito10, A. Rinaldi11, E. Maiello12, F. Ciardiello13

Author affiliations

  • 1 Cell Biology Unit, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 2 Oncologia Medica, Dipartimento Di Internistica Clinica E Sperimentale “f. Magrassi”,, Università degli Studi della Campania Luigi Vanvitelli, 80121 - Napoli/IT
  • 3 Oncologia Medica, Dipartimento Di Internistica Clinica E Sperimentale “f. Magrassi”,, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 4 Trial Office, GOIM, Bari/IT
  • 5 Oncologia Medica, Ospedale S. Giuseppe Moscati, Statte/IT
  • 6 Medical Oncology, Azienda Ospedaliera di Rilievo Nazionale "Antonio Cardarelli"-AORN A. Cardarelli, 80131 - Napoli/IT
  • 7 Medical Oncology, Azienda Ospedaliera ARNAS Garibaldi, 95100 - Catania/IT
  • 8 Medical Oncology, Istituto Tumori Giovanni Paolo II, 70126 - Bari/IT
  • 9 Geriatric Oncology, Ospedale Vito Fazzi, 73100 - Lecce/IT
  • 10 Oncology, Ospedale Riuniti di Foggia, 71100 - Foggia/IT
  • 11 Oncologia, ASL Taranto, 74011 - Castellaneta/IT
  • 12 Medical Oncology, IRCCS Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT
  • 13 Dipartimento Medico-chirurgico Di Internistica Clinica E Sperimentale "f. Magrassi E A. Lanzara", Università degli Studi della Campania "Luigi Vanvitelli", 80131 - naples/IT


Abstract 5073


Liquid biopsy can represent an alternative to tissue biopsy for biomarker testing in cancer pts. In addition, liquid biopsy can be used to monitor the response to treatment and the molecular evolution of the disease.


In the CAPRI GOIM trial, KRAS exon 2 wild type (wt) mCRC pts received first line cetuximab plus FOLFIRI. Tumor samples were assessed by Next Generation Sequencing (NGS) with the Ion AmpliSeq™ Lung and Colon Cancer Panel (Thermofisher). Plasma samples at baseline (n = 96), at 3 weeks of treatment (n = 54), at 6 weeks (n = 14) and at progression of disease (n = 24) were collected from 96 patients and analyzed for exon 2, 3 and 4 KRAS and NRAS mutations using BEAMing Digital PCR (Sysmex Inostics).


Analysis of basal plasma samples from the 96 pts included in this study showed a concordance of 79,2% with the tissue RAS status as defined by NGS. The 11 cases that were RAS mutant (mut) in tissue and wt in plasma had suboptimal plasma volume available for analysis (


These data suggest that liquid biopsy might better recapitulate the heterogeneity of mCRC and might be useful to monitor the response to therapy. Analysis are ongoing to evaluate the clinical significance of RAS mutations with low MAF.

Clinical trial identification

Eudract number: 2009-014041-81

Legal entity responsible for the study

Nicola Normanno


Merck Serono, Sysmex Inostics


N. Normanno: Participation to advisory boards and/or research funding from Amgen, AstraZeneca, Merck Serono, MSD, Qiagen, Roche, Sysmex. E. Martinelli, T. Troiani: Participation to advisory boards: Servier and Roche. E. Maiello: Participation to advisory boards: Merck Serono, Roche, Sanofi. F. Ciardiello: Participation to advisory boards and/or research funding from Amgen, Bayer, AstraZeneca, Merck Serono, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.